Large-scale, government-led cash transfer programs drove significant improvements in health outcomes across low- and ...

“We all see it in airplanes that the cleaners come in as we are leaving, and only have a limited amount of time, so wiping ...

“Without appropriate guidance, many dogs either forget or never learn how to have basic manners, leading to problem behaviors ...

Large-scale, government-led cash transfer programs drove significant improvements in health outcomes across low- and ...

Bezuclastinib plus Sutent significantly improved progression-free survival and objective response rates in Gleevec-resistant ...

Cogent Biosciences has cleared another phase 3 hurdle for lead asset bezuclastinib, teeing up an approval submission for a form of gastrointestinal cancer in the first half of next year.

Objective Response Rate (ORR) reported for bezuclastinib combination compared to 26% ORR for sunitinib monotherapy (p<0.0001) Safety profile of bezuclastinib combination was well tolerated with no ...

APTN Investigates correspondent Tom Fennario brings us the story of the ongoing water crisis that is plaguing communities in ...

Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 8:00 ...

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections ...

Detailed price information for Phathom Pharmaceuticals Inc (PHAT-Q) from The Globe and Mail including charting and trades.